Home > Boards > US Listed > Medical - Drugs > Abbvie (ABBV)

Good for ABBVIE delay for Gilead Sciences &

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Argaponis Member Profile
 
Followed By 0
Posts 43
Boards Moderated 0
Alias Born 08/12/20
160x600 placeholder
Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic ... PR Newswire (US) - 1/15/2021 9:00:00 AM
Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma GlobeNewswire Inc. - 1/13/2021 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/12/2021 4:32:13 PM
Allergan Aesthetics Enters Into Option to Acquire Cypris Medical PR Newswire (US) - 1/12/2021 4:05:00 PM
Dragonfly Therapeutics annonce l'option d'adhésion exercée par AbbVie concernant le médicament candidat d'immunothérapie ... PR Newswire (Canada) - 1/12/2021 12:35:00 PM
AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call PR Newswire (US) - 1/12/2021 8:00:00 AM
Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate PR Newswire (Canada) - 1/12/2021 6:45:00 AM
Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate PR Newswire (US) - 1/12/2021 6:45:00 AM
Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate PR Newswire (US) - 1/12/2021 6:45:00 AM
AbbVie: Skyrizi Phase 3 Crohn's Induction Studies Meet Main Endpoints Dow Jones News - 1/7/2021 9:56:00 AM
Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 I... PR Newswire (US) - 1/7/2021 8:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/6/2021 5:01:07 PM
AbbVie to Present at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire (US) - 1/6/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 5:03:55 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 5:03:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 5:02:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 5:02:37 PM
AbbVie Reports Positive Phase 3 Results of Skyrizi in Psoriatic Arthritis Dow Jones News - 1/5/2021 10:14:00 AM
Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Ps... PR Newswire (US) - 1/5/2021 8:48:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/31/2020 1:16:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/31/2020 1:15:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/31/2020 1:14:22 PM
IMBRUVICA® (ibrutinib) U.S. Prescribing Information Updated to Include Long-Term Data for Waldenström's Macroglobulinemia (... PR Newswire (US) - 12/23/2020 7:30:00 AM
US ITC Blocks Imports of Jeuveau Wrinkle Treatment -- Bloomberg Dow Jones News - 12/16/2020 7:09:00 PM
Santé Canada approuve l'indication de VENCLEXTA® (vénétoclax) en association avec l'azacitidine ou avec la cytarabine à ... PR Newswire (Canada) - 12/15/2020 7:30:00 AM
Argaponis   Wednesday, 08/19/20 09:45:13 AM
Re: None
Post # of 620 
Good for ABBVIE delay for Gilead Sciences & (galapagos) rheumatoid arthritis (RA)


Mechelen, Belgium; 19 August 2020, 01.25 CET; regulated information – Galapagos (Euronext & Nasdaq: GLPG) announces today that Gilead Sciences, Inc. (Nasdaq: GILD) received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA). The FDA issues CRLs to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form. Gilead is the market authorization holder for filgotinib in the United States and is responsible for potential commercialization in the U.S.

The FDA has requested data from the MANTA and MANTA-RAy studies before completing its review of the NDA. The MANTA and MANTA-RAy studies are designed to assess whether filgotinib has an impact on sperm parameters. The FDA also has expressed concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose.

“We are disappointed in this outcome and will evaluate the points raised in the CRL for discussion with the FDA. We continue to believe in the benefit/risk profile of filgotinib in RA, which has been demonstrated in the FINCH Phase 3 clinical program,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.

“This CRL issued by the FDA is very disappointing given the robust and comprehensive data package provided. Despite today’s news, we continue to believe filgotinib has the potential to provide an effective, new treatment option for patients with rheumatoid arthritis, where there remains a significant unmet need,” said Dr. Walid Abi-Saab, Chief Medical Officer, Galapagos.

The MANTA and MANTA-RAy studies are fully recruited, with topline results anticipated in the first half of 2021. Filgotinib is currently under review by regulatory authorities around the world. Filgotinib recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending marketing authorization for filgotinib in the EU for the treatment of adults with moderate to severe RA who have responded inadequately or are intolerant of one or more disease-modifying anti-rheumatic drugs.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences